RT Journal Article
SR Electronic
T1 Genetically predicted on-statin LDL response is associated with higher intracerebral hemorrhage risk
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.22.22272697
DO 10.1101/2022.03.22.22272697
A1 Mayerhofer, Ernst
A1 Malik, Rainer
A1 Parodi, Livia
A1 Burgess, Stephen
A1 Harloff, Andreas
A1 Dichgans, Martin
A1 Rosand, Jonathan
A1 Anderson, Christopher D
A1 Georgakis, Marios K
YR 2022
UL http://medrxiv.org/content/early/2022/03/23/2022.03.22.22272697.abstract
AB Statins lower low-density lipoprotein (LDL) cholesterol and are widely used for the prevention of atherosclerotic cardiovascular disease. Whether statin-induced LDL reduction increases risk of intracerebral hemorrhage (ICH) has been debated for almost two decades. Here, we explored whether genetically predicted on-statin LDL response is associated with ICH risk using Mendelian Randomization. Utilizing genomic data from randomized trials, we derived a polygenic score from 35 single nucleotide polymorphisms (SNP) of on-statin LDL response and tested it in the population-based UK-Biobank (UKB). We extracted statin drug and dose information from primary care data on a subset of 225,195 UKB participants covering a period of 29 years. We validated the effects of the genetic score on longitudinal LDL measurements with generalized mixed models and explored associations with incident ICH using Cox regression analysis. Statins were prescribed at least once to 75,973 (31%) of the study participants (mean 57 years, 55% females). Among statin users, mean LDL decreased by 3.45 mg/dl per year (95% CI: [-3.47, -3.42]) over follow-up. A higher genetic score of statin response (one SD increment) was associated with significant additional reductions in LDL levels (−0.05 mg/dl per year, [-0.07, -0.02]), showed concordant lipidomic effects on other lipid traits as statin use, and was associated with a lower risk for incident myocardial infarction (HR per SD increment 0.98 95% CI [0.96, 0.99]) and peripheral artery disease (HR per SD increment 0.92 95% CI [0.86, 0.98]). Over a 11-year follow-up period, a higher genetically predicted statin response among statin users was associated with higher ICH risk in a model adjusting for statin dose (HR per SD increment 1.15, 95% CI [1.04, 1.27]). On the contrary, there was no association with ICH risk among statin non-users (p=0.89). These results provide further support for the hypothesis that statin-induced LDL reduction may be causally associated with ICH risk. While the net benefit of statins for preventing vascular disease is well-established, these results provide insights about the personalized response to statin intake and the role of pharmacologic LDL-lowering in the pathogenesis of ICH.Competing Interest StatementJR has consulted for Pfizer, Inc. outside of the presented work. CDA has received sponsored research support from Bayer AG and Massachusetts General Hospital and has consulted for ApoPharma, Inc. outside of the presented work.Funding StatementMG is supported by a Walter-Benjamin fellowship from the German Research Foundation (Deutsche Forschungsgemeinschaft [DFG], GZ: GE 3461/1-1) and the FoeFoLe program of LMU Munich (FoeFoLe-Forschungsprojekt Reg.-Nr. 1120). CDA is supported by NIH R01NS103924, U01NS069673, AHA 18SFRN34250007, and AHA-Bugher 21SFRN812095 for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data that support the findings of this study are available from the UK Biobank and the GWAS for on-statin LDL (Postmus et al. Nat. Commun 2014)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the UK Biobank and the GWAS for on-statin LDL.GPGeneral PractitionerGWASGenome-wide Association StudyHDLHigh-density LipoproteinHRHazard RatioICHIntracerebral HemorrhageLDLLow-density lipoproteinMIMyocardial InfarctionMRMendelian RandomizationPADPeripheral Artery DiseaseSDStandard DeviationSNPSingle Nucleotide PolymorphismUKUnited KingdomUKBUK Biobank